Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
Results from the MONARCH 2 and MONALEESA-3 trials
Immunotherapy fails to improve PFS and OS in relapsed mesothelioma
Results from the PROMISE-meso trial presented
PARP inhibitors expand their role beyond BRCA mutations in first-line, newly diagnosed ovarian cancer
Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer
Towards diagnosis of minimal residual disease
Liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage cancers
Clinical benefits from antibody–drug conjugates are reported for bladder cancer
At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing